Acute mountain sickness prediction: a concerto of multidimensional phenotypic data and machine learning strategies in the framework of predictive, preventive, and personalized medicine.

IF 5.9 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
The EPMA journal Pub Date : 2025-03-31 eCollection Date: 2025-06-01 DOI:10.1007/s13167-025-00404-9
Wenhui Li, Meng Zhang, Yangyi Hu, Pan Shen, Zhijie Bai, Chaoji Huangfu, Zhexin Ni, Dezhi Sun, Ningning Wang, Pengfei Zhang, Li Tong, Yue Gao, Wei Zhou
{"title":"Acute mountain sickness prediction: a concerto of multidimensional phenotypic data and machine learning strategies in the framework of predictive, preventive, and personalized medicine.","authors":"Wenhui Li, Meng Zhang, Yangyi Hu, Pan Shen, Zhijie Bai, Chaoji Huangfu, Zhexin Ni, Dezhi Sun, Ningning Wang, Pengfei Zhang, Li Tong, Yue Gao, Wei Zhou","doi":"10.1007/s13167-025-00404-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Acute mountain sickness (AMS) is a self-limiting illness, involving a complex series of physiological responses to rapid ascent to high altitudes, where the body is exposed to lower oxygen levels (hypoxia) and changes in atmospheric pressure. AMS is the mildest and most common form of altitude sickness; however, without adequate preparation and adherence to ascent guidelines, it can progress to life-threatening conditions.</p><p><strong>Aims: </strong>Due to the multi-factorial predisposition of AMS among individuals, identifying AMS biomarkers before high altitude exposure from multiple dimensions (e.g., clinical, metabolic, and proteomic markers) and integrating them to build an AMS predictive model enables early diagnosis and personalized interventions, which allows targeted allocation of medical resources, such as prophylactic medications (e.g., acetazolamide) and supplemental oxygen, to those who need them most and prevention of unnecessary complications. Consequently, predicting AMS utilizing biomarkers from multidimensional phenotypic data before high-altitude exposure is essential for the paradigm change in high-altitude medical research from currently applied reactive services to the cost-effective predictive, preventive, and personalized medicine (PPPM/3PM) in primary (reversible damage to health and targeted protection against health-to-disease transition) and secondary (personalized protection against disease progression) care.</p><p><strong>Methods: </strong>To this end, this study recruited 83 Han Chinese male volunteers and obtained clinical, proteomic, and metabolomic profiles for analysis before they ascended to high altitudes. The Mann-Whitney <i>U</i> test was used to identify clinical features distinguishing AMS from non-AMS. The proteomic and metabolomic features were concatenated and clustered to find co-expression modules associated with AMS. A machine learning model, Mutual Information-radial kernel-based Support Vector Machine-Recursive Feature Elimination (MI-radialSVM-RFE) was employed for biomarkers selection and AMS prediction. A molecular docking technique was used to select molecular biomarkers that can bind with Traditional Chinese Medicine (TCM) ingredients.</p><p><strong>Results: </strong>Among 83 participants, 66 were selected for detailed analysis after quality control steps. Six protein-metabolite co-expression modules were identified as significantly associated with AMS. The MI-radialSVM-RFE model selected 12 biomarkers (two clinical features: systolic blood pressure (SBP) and peak expiratory flow (PEF); six proteins: Acyl-CoA synthetase long-chain family member 4 (ACSL4), immunoglobulin kappa variable 1D-16 (IGKV1D-16), coagulation factor XIII B subunit (F13B), prosaposin (PSAP), poliovirus receptor (PVR), and multimerin-2 (MMRN2); and four metabolites: 2-Methyl-1,3-cyclohexadiene, calcitriol, 4-Acetamido-2-amino-6-nitrotoluene, and 20-Hydroxy-PGE2) for the AMS prediction model. The model exhibited excellent predictive performance in both training (<i>n</i> = 66) and validating cohorts (<i>n</i> = 24) with AUCs of 0.97 and 0.94, respectively. Additionally, molecular docking analysis suggested PSAP and ACSL4 proteins as potential molecular targets for AMS prevention.</p><p><strong>Conclusion and expert recommendations: </strong>This study advances high-altitude medicine by developing a predictive model for AMS using clinical, proteomic, and metabolomic data. The identified biomarkers linked to energy metabolism, immune response, and vascular regulation offer insights into AMS mechanisms. High-altitude predictive approaches should focus on implementing biomarker-driven risk screening using clinical, proteomic, and metabolomic data to identify high-risk individuals before high-altitude exposure. Preventive measures should prioritize pre-acclimatization protocols, tailored nutritional strategies and interventions guided by biomarker profiles, and lifestyle adjustments, such as maintaining mitochondrial health through proper nutritional strategies.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13167-025-00404-9.</p>","PeriodicalId":94358,"journal":{"name":"The EPMA journal","volume":"16 2","pages":"265-284"},"PeriodicalIF":5.9000,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12106293/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The EPMA journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13167-025-00404-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Acute mountain sickness (AMS) is a self-limiting illness, involving a complex series of physiological responses to rapid ascent to high altitudes, where the body is exposed to lower oxygen levels (hypoxia) and changes in atmospheric pressure. AMS is the mildest and most common form of altitude sickness; however, without adequate preparation and adherence to ascent guidelines, it can progress to life-threatening conditions.

Aims: Due to the multi-factorial predisposition of AMS among individuals, identifying AMS biomarkers before high altitude exposure from multiple dimensions (e.g., clinical, metabolic, and proteomic markers) and integrating them to build an AMS predictive model enables early diagnosis and personalized interventions, which allows targeted allocation of medical resources, such as prophylactic medications (e.g., acetazolamide) and supplemental oxygen, to those who need them most and prevention of unnecessary complications. Consequently, predicting AMS utilizing biomarkers from multidimensional phenotypic data before high-altitude exposure is essential for the paradigm change in high-altitude medical research from currently applied reactive services to the cost-effective predictive, preventive, and personalized medicine (PPPM/3PM) in primary (reversible damage to health and targeted protection against health-to-disease transition) and secondary (personalized protection against disease progression) care.

Methods: To this end, this study recruited 83 Han Chinese male volunteers and obtained clinical, proteomic, and metabolomic profiles for analysis before they ascended to high altitudes. The Mann-Whitney U test was used to identify clinical features distinguishing AMS from non-AMS. The proteomic and metabolomic features were concatenated and clustered to find co-expression modules associated with AMS. A machine learning model, Mutual Information-radial kernel-based Support Vector Machine-Recursive Feature Elimination (MI-radialSVM-RFE) was employed for biomarkers selection and AMS prediction. A molecular docking technique was used to select molecular biomarkers that can bind with Traditional Chinese Medicine (TCM) ingredients.

Results: Among 83 participants, 66 were selected for detailed analysis after quality control steps. Six protein-metabolite co-expression modules were identified as significantly associated with AMS. The MI-radialSVM-RFE model selected 12 biomarkers (two clinical features: systolic blood pressure (SBP) and peak expiratory flow (PEF); six proteins: Acyl-CoA synthetase long-chain family member 4 (ACSL4), immunoglobulin kappa variable 1D-16 (IGKV1D-16), coagulation factor XIII B subunit (F13B), prosaposin (PSAP), poliovirus receptor (PVR), and multimerin-2 (MMRN2); and four metabolites: 2-Methyl-1,3-cyclohexadiene, calcitriol, 4-Acetamido-2-amino-6-nitrotoluene, and 20-Hydroxy-PGE2) for the AMS prediction model. The model exhibited excellent predictive performance in both training (n = 66) and validating cohorts (n = 24) with AUCs of 0.97 and 0.94, respectively. Additionally, molecular docking analysis suggested PSAP and ACSL4 proteins as potential molecular targets for AMS prevention.

Conclusion and expert recommendations: This study advances high-altitude medicine by developing a predictive model for AMS using clinical, proteomic, and metabolomic data. The identified biomarkers linked to energy metabolism, immune response, and vascular regulation offer insights into AMS mechanisms. High-altitude predictive approaches should focus on implementing biomarker-driven risk screening using clinical, proteomic, and metabolomic data to identify high-risk individuals before high-altitude exposure. Preventive measures should prioritize pre-acclimatization protocols, tailored nutritional strategies and interventions guided by biomarker profiles, and lifestyle adjustments, such as maintaining mitochondrial health through proper nutritional strategies.

Supplementary information: The online version contains supplementary material available at 10.1007/s13167-025-00404-9.

Abstract Image

Abstract Image

Abstract Image

急性高原病预测:多维表型数据和机器学习策略在预测,预防和个性化医学框架的协奏曲。
背景:急性高原病(AMS)是一种自限性疾病,涉及对快速上升到高海拔地区的一系列复杂的生理反应,在那里身体暴露于低氧水平(缺氧)和大气压力的变化。AMS是最轻微和最常见的高原反应;然而,如果没有充分的准备和坚持攀登指南,它可能会发展到危及生命的状况。目的:由于AMS在个体中的多因素易感性,从多个维度(如临床、代谢和蛋白质组学标记)识别高海拔暴露前的AMS生物标志物,并将其整合到AMS预测模型中,可以实现早期诊断和个性化干预,从而有针对性地分配医疗资源,如预防性药物(如乙酰唑胺)和补充氧气。给那些最需要的人,预防不必要的并发症。因此,在高海拔暴露前利用来自多维表型数据的生物标志物预测AMS对于高海拔医学研究范式的转变至关重要,从目前应用的反应性服务到具有成本效益的预测、预防和个性化医疗(PPPM/3PM),主要(对健康的可逆损害和针对健康向疾病转变的针对性保护)和次要(针对疾病进展的个性化保护)护理。方法:为此,本研究招募了83名汉族男性志愿者,获得了他们的临床、蛋白质组学和代谢组学特征,并对其进行了分析。Mann-Whitney U检验用于鉴别AMS与非AMS的临床特征。将蛋白质组学和代谢组学特征进行连接和聚类,以寻找与AMS相关的共表达模块。采用基于互信息径向核的支持向量机递归特征消除(MI-radialSVM-RFE)机器学习模型进行生物标志物选择和AMS预测。采用分子对接技术筛选可与中药成分结合的分子生物标志物。结果:83名受试者中,经质控步骤筛选出66名进行详细分析。鉴定出6个蛋白代谢物共表达模块与AMS显著相关。MI-radialSVM-RFE模型选择了12个生物标志物(两个临床特征:收缩压(SBP)和呼气峰流量(PEF);6种蛋白:酰基辅酶a合成酶长链家族成员4 (ACSL4)、免疫球蛋白kappa变量1D-16 (IGKV1D-16)、凝血因子XIII B亚基(F13B)、丙苷(PSAP)、脊髓灰质炎病毒受体(PVR)、多聚蛋白2 (MMRN2);以及4种代谢物:2-甲基-1,3-环己二烯、骨化三醇、4-乙酰氨基-2-氨基-6-硝基甲苯和20-羟基pge2),用于AMS预测模型。该模型在训练队列(n = 66)和验证队列(n = 24)中均表现出优异的预测性能,auc分别为0.97和0.94。此外,分子对接分析表明PSAP和ACSL4蛋白可能是AMS预防的潜在分子靶点。结论和专家建议:本研究利用临床、蛋白质组学和代谢组学数据建立了AMS的预测模型,从而推动了高原医学的发展。已确定的与能量代谢、免疫反应和血管调节相关的生物标志物为AMS的机制提供了新的见解。高海拔预测方法应侧重于利用临床、蛋白质组学和代谢组学数据实施生物标志物驱动的风险筛查,以在高海拔暴露前识别高风险个体。预防措施应优先考虑预适应方案、量身定制的营养策略和生物标志物特征指导下的干预措施,以及生活方式调整,例如通过适当的营养策略维持线粒体健康。补充信息:在线版本包含补充资料,可在10.1007/s13167-025-00404-9获得。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
12.50
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信